With new antibiotic technology already yielding positive results, a start-up firm called TetraPhase Pharmaceuticals Inc. raised $25 million in its first round of venture capital backing. (BioWorld Today)
With new antibiotic technology already yielding positive results, a start-up firm called TetraPhase Pharmaceuticals Inc. raised $25 million in its first round of venture capital backing. (BioWorld Today)
The FDA granted a broader label to Herceptin (trastuzumab), paving the way for Genentech Inc. to promote its most visible targeted oncology product as a front-line treatment for breast cancer.(BioWorld Today)
The FDA granted a broader label to Herceptin (trastuzumab), paving the way for Genentech Inc. to promote its most visible targeted oncology product as a front-line treatment for breast cancer.(BioWorld Today)
